Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icatibant in hospitalized COVID-19 pneumonia
NCT04978051Phase 2Completed
- Start
- Apr 2021
- Primary completion
- Nov 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in COVID-19 pneumonia comparing Standard of Care (SoC) with SoC + Icatibant (2 arms). Primary endpoints: Efficacy of experimental treatment at 10 days and Safety of experimental treatment at 10 days. Started Apr 2021; status: completed.
02
Drugs
icatibant
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04978051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04978051.